Santo was founded and is led by a team of biopharmaceutical entrepreneurs, executives, and scientists from leading academic and research institutions worldwide. The company has developed three core technology platforms—STLenti®, an advanced lentiviral vector delivery system; STPDX®, a comprehensive disease model platform; and STProd®, a state-of-the-art process optimization platform. These platforms work together to provide strong technical support for innovative drug development. Santo is committed to improving drug safety, optimizing production efficiency, and reducing treatment costs, with the ultimate goal of making advanced gene therapies accessible to a broader patient population.